Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.

Publication ,  Journal Article
Sniderman, AD; Thanassoulis, G; Glavinovic, T; Navar, AM; Pencina, M; Catapano, A; Ference, BA
Published in: JAMA Cardiol
December 1, 2019

IMPORTANCE: The conventional model of atherosclerosis presumes that the mass of cholesterol within very low-density lipoprotein particles, low-density lipoprotein particles, chylomicron, and lipoprotein (a) particles in plasma is the principal determinant of the mass of cholesterol that will be deposited within the arterial wall and will drive atherogenesis. However, each of these particles contains one molecule of apolipoprotein B (apoB) and there is now substantial evidence that apoB more accurately measures the atherogenic risk owing to the apoB lipoproteins than does low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol. OBSERVATIONS: Cholesterol can only enter the arterial wall within apoB particles. However, the mass of cholesterol per apoB particle is variable. Therefore, the mass of cholesterol that will be deposited within the arterial wall is determined by the number of apoB particles that are trapped within the arterial wall. The number of apoB particles that enter the arterial wall is determined primarily by the number of apoB particles within the arterial lumen. However, once within the arterial wall, smaller cholesterol-depleted apoB particles have a greater tendency to be trapped than larger cholesterol-enriched apoB particles because they bind more avidly to the glycosaminoglycans within the subintimal space of the arterial wall. Thus, a cholesterol-enriched particle would deposit more cholesterol than a cholesterol-depleted apoB particle whereas more, smaller apoB particles that enter the arterial wall will be trapped than larger apoB particles. The net result is, with the exceptions of the abnormal chylomicron remnants in type III hyperlipoproteinemia and lipoprotein (a), all apoB particles are equally atherogenic. CONCLUSIONS AND RELEVANCE: Apolipoprotein B unifies, amplifies, and simplifies the information from the conventional lipid markers as to the atherogenic risk attributable to the apoB lipoproteins.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

December 1, 2019

Volume

4

Issue

12

Start / End Page

1287 / 1295

Location

United States

Related Subject Headings

  • Risk Assessment
  • Randomized Controlled Trials as Topic
  • Mendelian Randomization Analysis
  • Humans
  • Coronary Artery Disease
  • Cholesterol, VLDL
  • Cholesterol, LDL
  • Cholesterol Ester Transfer Proteins
  • Cardiovascular Diseases
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019). Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol, 4(12), 1287–1295. https://doi.org/10.1001/jamacardio.2019.3780
Sniderman, Allan D., George Thanassoulis, Tamara Glavinovic, Ann Marie Navar, Michael Pencina, Alberico Catapano, and Brian A. Ference. “Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.JAMA Cardiol 4, no. 12 (December 1, 2019): 1287–95. https://doi.org/10.1001/jamacardio.2019.3780.
Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019 Dec 1;4(12):1287–95.
Sniderman, Allan D., et al. “Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.JAMA Cardiol, vol. 4, no. 12, Dec. 2019, pp. 1287–95. Pubmed, doi:10.1001/jamacardio.2019.3780.
Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019 Dec 1;4(12):1287–1295.

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

December 1, 2019

Volume

4

Issue

12

Start / End Page

1287 / 1295

Location

United States

Related Subject Headings

  • Risk Assessment
  • Randomized Controlled Trials as Topic
  • Mendelian Randomization Analysis
  • Humans
  • Coronary Artery Disease
  • Cholesterol, VLDL
  • Cholesterol, LDL
  • Cholesterol Ester Transfer Proteins
  • Cardiovascular Diseases
  • Biomarkers